Subscribe
shutterstock_1349460611_pavel_kapysh-1-1
Pavel Kapysh / Shutterstock.com
18 August 2022AmericasStaff Writer

Bausch Health unit prevails in patent dispute

New Jersey court dismissed a suit regarding an oral antibiotic | Prior art invalidated plaintiff’s four patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent